Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2664 results

Media Release / Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
Key Release / Jul 18, 2018
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
Media Release / Jul 23, 2018
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
Media Release / Jul 19, 2018
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
Media Release / Jul 27, 2018
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
Media Release / Jul 27, 2018
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
Key Release / Aug 14, 2018
Novartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer
Basel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von…
Media Release / Jul 30, 2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
Media Release / May 31, 2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
Media Release / May 31, 2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data…